Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany.

[1] In the following years, Medigene acquired several other biotechnology companies, including NeuroVir and Avidex, and received regulatory approval for its cancer drug Eligard in Germany.

[1] In 2006, Medigene's product Veregen became the first FDA-approved biopharmaceutical from a German biotech company in the United States.

In 2015, Medigene started a Phase I/II clinical trial with its DC vaccine (FDC101) to treat acute myeloid leukemia.

[1][2] In 2019, Medigene partnered with Roivant and Sinovant to launch Cytovant Sciences, which focuses on developing cellular therapies in Asia.